» Articles » PMID: 33817311

MiR-338-3p Inhibits Cell Growth, Invasion, and EMT Process in Neuroblastoma Through Targeting MMP-2

Overview
Journal Open Life Sci
Specialty Biology
Date 2021 Apr 5
PMID 33817311
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

This study aimed to explore the regulatory mechanisms of miR-338-3p and matrix metalloproteinase-2 (MMP-2) in neuroblastoma. Putative target interaction regions of miR-338-3p on MMP-2 were predicted by miRcode and miRbase bioinformatics tools. Relative expression of miRNA-338-3p and MMP-2 in neuroblastoma tissues and GI-LI-N and SK-N-SH cells was determined by reverse transcription polymerase chain reaction experiment. Furthermore, the cell proliferation was determined by Cell Counting Kit-8 assay, the cell apoptosis rate was analyzed by flow cytometry assay, and the cell invasion was evaluated by transwell assay. miR-338-3p expression was downregulated, whereas MMP-2 expression was upregulated in metastasis tissue site compared to that in primary tissue site in total. Furthermore, miR-338-3p overexpression suppressed proliferation, invasion, and epithelial-mesenchymal transition (EMT) of neuroblastoma cells but promoted apoptosis, and the knockdown of MMP-2 triggered similar effects. Furthermore, MMP-2 was directly targeted by miR-338-3p, and overexpression of MMP-2 rescued the inhibitory effects of miR-338-3p on human neuroblastoma cell progression. Collectively, these data demonstrated that miR-338-3p could suppress cell growth, invasion, and EMT pathway and induce apoptosis in neuroblastoma cells by targeting MMP-2. MiR-338-3p sponged MMP-2 to regulate the PI3K/AKT pathway in human neuroblastoma cells.

Citing Articles

Relationship between serum level of miR-338-3p and miR-105-3p and bone metabolic markers in patients with diabetes nephropathy.

Liu J, Zhang Y, Dai L Ren Fail. 2024; 46(2):2406390.

PMID: 39378116 PMC: 11463021. DOI: 10.1080/0886022X.2024.2406390.


Generation of Novel Immunocompetent Mouse Cell Lines to Model Experimental Metastasis of High-Risk Neuroblastoma.

Dhamdhere M, Spiegelman D, Schneper L, Erbe A, Sondel P, Spiegelman V Cancers (Basel). 2023; 15(19).

PMID: 37835389 PMC: 10571844. DOI: 10.3390/cancers15194693.


Role of non-coding RNAs in neuroblastoma.

Anoushirvani A, Jafarian Yazdi A, Amirabadi S, Ahmadi Asouri S, Shafabakhsh R, Sheida A Cancer Gene Ther. 2023; 30(9):1190-1208.

PMID: 37217790 DOI: 10.1038/s41417-023-00623-0.


The hsa_circ_0039857/miR-338-3p/RAB32 axis promotes the malignant progression of colorectal cancer.

Xu P, Cheng S, Wang X, Jiang S, He X, Tang L BMC Gastroenterol. 2022; 22(1):530.

PMID: 36539702 PMC: 9764720. DOI: 10.1186/s12876-022-02622-1.


The Extracellular Matrix and Neuroblastoma Cell Communication-A Complex Interplay and Its Therapeutic Implications.

Horwacik I Cells. 2022; 11(19).

PMID: 36231134 PMC: 9564247. DOI: 10.3390/cells11193172.


References
1.
Pastor E, Mousa S . Current management of neuroblastoma and future direction. Crit Rev Oncol Hematol. 2019; 138:38-43. DOI: 10.1016/j.critrevonc.2019.03.013. View

2.
Liu W, Ren H, Ren J, Yin T, Hu B, Xie S . The role of EGFR/PI3K/Akt/cyclinD1 signaling pathway in acquired middle ear cholesteatoma. Mediators Inflamm. 2013; 2013:651207. PMC: 3839121. DOI: 10.1155/2013/651207. View

3.
Pinto N, Applebaum M, Volchenboum S, Matthay K, London W, Ambros P . Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015; 33(27):3008-17. PMC: 4567703. DOI: 10.1200/JCO.2014.59.4648. View

4.
Chen X, Pan M, Han L, Lu H, Hao X, Dong Q . miR-338-3p suppresses neuroblastoma proliferation, invasion and migration through targeting PREX2a. FEBS Lett. 2013; 587(22):3729-37. DOI: 10.1016/j.febslet.2013.09.044. View

5.
Ratner N, Brodeur G, Dale R, Schor N . The "neuro" of neuroblastoma: Neuroblastoma as a neurodevelopmental disorder. Ann Neurol. 2016; 80(1):13-23. PMC: 5419586. DOI: 10.1002/ana.24659. View